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1. Introduction 
Pancreato-biliary cancers are relatively uncommon and in general, including cancers arise 
from the pancreas, bile duct and major ampullae. These tumours are uniformly carried a 
poor prognosis due to late presentation and surgical resection is only possible in less than 
20% patients (David et al., 2009; Luke et al., 2009). Despites many medical advances in the 
imaging diagnosis, chemo-radio-therapy, surgical technique and post-operative care over 
the last 2 decades, the overall survival of patients with pancreato-biliary neoplasm has not 
improved significantly (Luke et al., 2009). The aim of the current chapter is to review and 
discuss current techniques and approaches to the diagnosis and management of pancreato-
biliary neoplasm. 
2. Clinico-pathology of pancreato-biliary tumours 
2.1 Pancreatic carcinoma 
In the Western world, pancreatic cancer is the fourth leading cause of cancer related 
mortality with the approximate incidence of 11 per 100 000, and ranks second after 
colorectal cancer among all gastrointestinal malignancies (Shaib et al., 2006). Men are more 
frequently affected than women and over 80% patients are diagnosed at the age older than 
60 years. Almost 50% patients have distant metastases at the time of presentation with poor 
5-year survival of 5% (Shaib et al., 2006). Recent data suggest that although the mortality 
rate for males has decreased by 0.4% from 1990 to 2005, the mortality rate for females has 
increased by 4.4% (Shaib et al., 2006; Jemal et al., 2009). The reason for this gender difference 
in mortality is unknown. Risk factors for pancreatic cancer include smoking, alcohol, 
diabetes mellitus, chronic pancreatitis, family history of pancreatic cancer. Patients with 
hereditary pancreatitis, Puetz-Jeghers syndrome, familial atypical multiple mole melanoma, 
familial breast and ovarian cancer, Li-Fraumeni syndrome, Fanconi anaemia, ataxia-
telangiectasia, familial adenomatous polyposis, cystic fibrosis and possible hereditary non-
polyposis colon cancer syndrome are also at higher risk of having pancreatic cancer (Shaib 
et al., 2006; Klapman and Malafa, 2008).  
Ductal infiltrating adenocarcinoma is the most common type of pancreatic cancer with 78% 
located in the head, 11% in the body and 11% in the tail (Lillemoe et al., 2000; Ghaneh et al., 
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2008). Less than 15% of pancreatic cancers are intraductal mucinous papillary neoplasm 
(IPMN), solid pseudopapillary neoplasm, pancreatoblastoma, mucinous 
cystadenocarcinoma, adenosquamous carcinoma and acinar cell carcinoma (Ghaneh et al., 
2008). Given the preponderance pancreatic head location of the tumours, painless cholestatic 
symptoms are the most common presentation (Ghaneh et al., 2008). Anorexia, abdominal 
pain or mass and weight loss often indicate the presence of advanced disease. 
2.2 Cholangiocarcinoma 
This is rare malignant disease of the epithelial cells in the intra- and extrahepatic bile ducts and 
the incidence is increasing, especially the intra-hepatic subtype (Patel, 2001). In addition to 
liver flukes infestation, hepatitis B and C infections have recently been associated with rise of 
cholangiocarcinoma in the developing countries, and are thought to be responsible for the 
increasing incidence of intra-hepatic cholangiocarcinomas. In the western countries, primary 
sclerosing cholangitis and congenital anomalies such as Caroli’s syndrome and choledochal 
cysts are the main predisposing risk factors for cholangiocarcinoma (Patel, 2006).  
As with pancreatic cancer, most of the cholangiocarcinomas are unresectable at presentation 
and the prognosis for these patients is dismal. Clinical presentations of cholangiocarcinoma 
are dependent on tumour location (Patel, 2006). Extrahepatic tumours, including those 
involving the bifurcation usually show signs of biliary obstruction with jaundice and pale 
stools. In contrast, intra-hepatic cholangiocarcinomas more often present with late 
symptoms of malignancy such as weight loss, loss of appetite, and abdominal pain or mass. 
2.3 Ampullary tumours 
Compared to pancreatic carcinoma and cholangiocarcinoma, ampullary neoplasm is the 
least common and aggressive tumour. In general, ampullary tumour has better clinical 
outcomes even when the tumour is not resectable (Heinrich and Clavien 2010). Whilst 
ampullary tumours can occur sporadically, they are often seen in the context of genetic 
syndromes such as familial adenomatous polyposis and hereditary non-polyposis colorectal 
cancer, in whom the risk is 100 times more than the general population (Offerhaus et al., 
1992). As endoscopic screening and surveillance program is adopted for these at-risk 
individuals, most tumours are adenomas at detection, though the potential of malignant 
transformation to carcinomas is high (Jean and Dua, 2003; Fischer and Zhou, 2004). 
Currently, there is no consensus on the management of ampullary tumors. Factors that 
impact treatment strategy include the patient’s general health, tumor characteristics, and 
available expertise. Ampullary adenomas, especially those with high-grade dysplasia, 
warrant therapy because they are “time bombs” for malignancy and may already harbor 
malignancy missed on biopsy (Heinrich and Clavien 2010). Although endoscopic resection 
is widely embraced as first-line therapy in patients with benign ampullary tumors 
(Binmoeller et al., 1993; Beger et al., 1999; Cheng et al., 2004), the final treatment decision is 
based on the histological findings of the ampullectomized specimen. The presence of 
invasive carcinoma in the specimen indicates the need for definitive surgical resection. In 
patients who are poor candidates for surgery or who refuse surgery, endoscopic resection 
with ablative therapy can be considered despite unfavorable tumor characteristics (Nguyen 
et al. 2010). Endoscopic ampullectomy has also been reported to successfully eradicate large 
ampullary adenomas (Zadorova et al., 2001), early T1 ampullary adenocarcinoma 
www.intechopen.com
 Pancreato-Biliary Cancers – Diagnosis and Management 
 
463 
(Katsinelos et al., 2007), and even lesions with intraductal growth (Bohnacker et al., 2005). 
Given its tumour behaviour, clinical presentation and treatment modality are very different 
to that of pancreatic cancer and cholangiocarcinoma, ampullary tumours will not be 
discussed further in this chapter. 
3. Investigations of pancreato-biliary cancers 
The imaging modalities involve in the detection, staging and management of pancreatic 
cancer are computer tomography (CT), magnetic resonance imaging (MRI), endoscopic 
retrograde cholangiopancreatography (ERCP), endoscopic ultrasound (EUS) and positron 
emission tomography (PET) (Clarke et al., 2003; Chang et al., 2009; Peddu et al., 2009). The 
diagnosis can potentially be made by any, or a combination of the above modalities. The 
roles and relative importance of these imaging modalities have changed over the last few 
decades and continue to change with rapid technological advancement in medical imaging.  
Base on current best available evidence, CT should be used as first line for diagnosis, staging 
and the assessment of resectability in pancreato-biliary cancer. MRI should be reserved for 
patients with iodine contrast allergy or who cannot be exposed to radiation or to be used as 
an adjunct to CT in patients with suspicious liver lesions that need to be to better 
characterized (Clarke et al., 2003; Peddu et al., 2009). MR cholangio-pancreatography 
(MRPC) is an essential part of the evaluation for cholangiocarcinoma as it can identify the 
luminal involvement of the cancer as well as the road map of the biliary tree (Patel, 2006). 
Such information is not only important in local staging but also critical in determining 
respectability, type of surgery and/or identifying the dominant obstructive ductal system 
for biliary drainage. In selected cases, cholangioscopy is helpful by providing direct 
endoscopic visualization of the intra-ductal lesion that responsible for the biliary stricture 
(Patel, 2006). The recent development of SpyGlass cholangioscopy system has also allowed 
tissue sample under direct vision. 
EUS should be used for local staging and assessment of resectability if it remains 
inconclusive on non-invasive imaging modalities (Chang et al., 2009; Iglesias Garcia et al., 
2009). It should also be used in patients with a high clinical suspicion of a lesion that has not 
been clearly demonstrated using other modalities. EUS-FNA should also be the biopsy route 
of choice in patients where a tissue diagnosis or tissue from regional lymph nodes may alter 
the course of treatment, or if neo-adjuvant treatment is contemplated. If there is 
disagreement between CT and EUS images, then laparotomy and trial of dissection should 
be considered (Chang et al., 2009). PET/CT should be used selectively such as when 
metastatic disease is suspected but has not been demonstrated with other imaging 
modalities (Nguyen and Bartholomeusz, 2011; Serrano et al. 2010). The availability and local 
expertise of each imaging modality will also influence their use. A suggested management 
algorithm for patients with suspected pancreato-biliary cancer is shown in Figure 1. 
3.1 Tumour markers 
The role of tumour marker in the diagnosis and management of pancreato-biliary cancers 
remains controversial (Balzano and Di Carlo, 2008). Carbohydrate antigen 19-9 (CA19-9), 
which is caused by the up-regulation of glycosyl transferase genes, is the most commonly 
used marker and can provide useful diagnostic and prognostic information (Duffy et al.  
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Fig. 1. Suggested algorithm for the evaluation and management of patients with suspected 
pancreatic. 
2010). Its sensitivity (70%-90%) and specificity (43%-91%) for diagnosing pancreatic cancer 
are only modest and can be falsely increased by high serum bilirubin (Duffy et al. 2010). 
However, for those with confirmed pancreatic cancer, high serum CA19-9 is associated with 
a worse survival (Park et al., 2008). Similarly, in patients who undergo curative resection for 
pancreatic cancer, a normalizing post-operative CA19-9 level is associated with a longer 
median and disease-free survival compared to those with persistently high level (Duffy et 
al., 2008; Balzano and Di Carlo, 2008).  
3.2 Tissue sampling 
A distinct advantage of EUS is its ability to obtain tissue via fine needle aspiration (FNA). 
This approach is superior to percutaneous biopsy (via US or CT guided) in the investigation 
of pancreato-biliary malignancies with higher diagnostic yield (84% vs. 62%) and 
significantly lower risk of tumour seeding from the needle tract (<2% vs. 16%) (Paquin et al., 
2005). Apart from biopsy of the primary tumour, it also has the ability to biopsy lymph 
nodes, liver lesions and ascitic fluid, which is critical in accurate staging and avoiding 
unnecessary resection (Figure 2). For pancreatic head lesions, the possibility of seeding is 
eliminated, as the needle track is included in the resection specimen (Yamao et al., 2005). In  
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Fig. 2. Examples of EUS-guide FNA of a pancreatic mass in the body (panel A), a liver lesion 
(panel B) and pathological celiac node (panel C). 
contrast, for lesions in the pancreatic body and tail, where the needle track is not resected, 
the risks and benefits of pre-operative biopsy should be carefully assessed on an individual 
basis. Due to its anatomical position, tissue acquisition from biliary lesion via EUS guided 
FNA is more difficult and in general, the diagnostic yield is lower than that for pancreatic 
cancer and is dependent on the location of the lesion. As it is easier to visualize and access 
the distal biliary lesions, the diagnostic yield is significantly higher in distal compared with 
proximal lesions (81% vs 59%) (Mohamadnejad et al. 2011).  
3.3 Cholangioscopy 
In cases where the diagnosis of the biliary stricture remains unclear after conventional 
MDCT, MRI and EUS evaluation, directly visualization of the appearance of the ductal 
strictures and biopsy can be helpful in differentiating benign from malignant disorders 
(Figure 3). Although video “mother-baby” cholangioscope provides high quality images, it 
is fragile and often lack of accessory channel for tissue sampling (Nguyen, 2009; Nguyen et 
al., 2009). The diagnostic yield of malignancy based on cholangioscopic appearance of the 
intra-ductal lesion varied from 70% to 88% (Nguyen, 2009; Nguyen et al., 2009). Currently, 
tissue sampling is only possible with the single-operator disposable SpyGlass system, which 
has a 1.2mm accessory channel. Although SpyGlass guided tissue sample is successful in up 
to 96% of cases, its overall accuracy in confirming a malignant stricture is only modest (49% 
of cases) (Nguyen, 2009; Nguyen et al., 2009). This is mainly due to the poor sensitivity of 
SpyGlass guided biopsy in the diagnosis of malignancy from extrinsic cancers (8%) as 
compared to that of intrinsic cancers (66%) (Nguyen, 2009; Nguyen et al., 2009).  
4. Therapeutic approaches for pancreato-biliary cancers 
Patients with suspected or confirmed diagnosis of pancreato-biliary malignancy should  
be assessed by a multidisciplinary team and stratified as resectable, borderline resectable,  
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Fig. 3. Cholangioscopic images from SpyScope for investigation of suspected biliary 
strictures. A case of a hepatoma causing a polypoid protrusion into the right hepatic duct at 
the hilum, mimicking a cholangiocarcinoma on cholangiography (panel A). A case of 
cholangiocarcinoma in the upper common bile duct (CBD) stricture, confirmed on SpyGlass 
guided biopsy (panel B). A case of mid-CBD stricture in a patient with primary sclerosing 
cholangitis, which appeared benign on SpyScope and was confirmed on biopsy (panel C).  
locally advanced unresectable or metastatic disease. Treatment should be planned according 
to local expertise and established guidelines, as resectable and borderline patients should be 
referred to surgeons, unresectable and metastatic patients should be referred to medical and 
radiation oncologists and palliative care teams. Endoscopic interventions to alleviate biliary 
or duodenal obstruction are also important in improving the performance status and quality 
of life in these patients. A multidisciplinary approach to pancreato-biliary malignancy is 
necessary to improve the overall outcome of these patients, especially for borderline 
resectable or unresectable disease as neo-adjuvant chemo-radiation therapy may play a role 
in down-staging and the conversion to potentially resectable, and in some case “curable”, 
disease (Verslype et al., 2007; Chang et al., 2008). The therapeutic approach for pancreatic 
cancers is summarized in Figure 1. 
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4.1 Surgery 
Surgical resection remains the only possibility of cure for pancreato-biliary cancers as 
chemotherapy and radiotherapy offering only a modest survival benefit. Patients who 
undergo complete surgical resection for localized, non-metastatic adenocarcinoma of the 
pancreas have a 5-year survival rate of approximately 20 to 25%, and a median survival of 
22 months (Cameron et al., 2006). Unfortunately less than 20% of patients with pancreatic 
cancer have disease amendable to surgical resection at the time of presentation (Yeo et al., 
1997) because patients often present at an advanced stage with widespread metastatic or 
locally advanced disease. The type of resection depends on the location of the tumours with 
Whipple’s procedures are most commonly performed as most cancers locate in the head of 
pancreas. 
Similarly, the type and extend of resection for cholangiocarcinoma depends on the location 
of the tumour. The indication and type of resection of intra-hepatic cholangiocarcinoma is 
similar to those of liver cancers. In contrast, curative surgery for extra-hepatic 
cholangiocarcinoma is rare and is only possible for distal ductal tumours (Witzigmann et al., 
2008; Lang et al., 2009). Hilar tumours involving the bifurcation are usually contraindicated 
for surgery and have very poor prognosis. Even in patients whose resection is considered 
successful, the overall five-year survival rate in the range of 25–30% (Lang et al., 2009).  
4.2 Chemo-radiotherapy 
Given the high loco-regional recurrence rate and a tendency towards early liver 
metastasis after pancreatic resection, adjuvant chemotherapy has been employed though 
its benefits remain controversial with mixed results until recently (Brennan, 2004; 
Zuckerman and Ryan, 2008). Of the six randomized controlled trials that examined the 
effects of adjuvant chemotherapy after pancreatic resection (Kalser and Ellenberg, 1985; 
Moertel et al., 1994; Neoptolemos et al., 2001; Neoptolemos et al., 2004; Oettle et al., 2007; 
Regine et al., 2008), only two trials were able to demonstrate a survival benefit of adjuvant 
chemotherapy (Neoptolemos et al., 2001; Neoptolemos et al., 2004). In the ESPAC-1 study, 
the survival of patients treated with adjuvant 5-Fluorouracil (5-FU) was significantly 
longer than that without adjuvant chemotherapy (20.1 months vs 15.5 months) 
(Neoptolemos et al., 2001; Neoptolemos et al., 2004). Subsequent meta-analysis supports 
the results of ESPAC-1 trial and indicated that 5-FU reduced the risk of death by 25% 
(Stocken et al., 2005). More recently, German investigators (Oettle et al., 2007) have 
demonstrated a disease-free survival advantage of patients who received gemcitabine 
adjuvant chemotherapy (13.4 months vs 6.9 months), but not the overall survival (22.1 
months vs 20.2 months). Given the encouraging data from these trials (Neoptolemos et al., 
2001; Neoptolemos et al., 2004; Oettle et al., 2007), adjuvant chemotherapy with either 5-
FU or gemcitabine or both is increasingly used in patients with resected pancreatic cancer 
(Fogelman et al., 2004; Goldstein et al., 2004). Compared with 5-FU, gemcitabine is better 
tolerated with lesser incidence of grade 3 and 4 haematological toxicity (Oettle et al., 2007; 
Palmer et al., 2007). 
Similarly, in order to convert borderline resectable to resectable tumors or to increase the 
probability of complete microscopic tumor resection, neo-adjuvant chemo-radiotherapy has 
also been evaluated (Gillen et al., 2010; Heinrich et al., 2010; van Tienhoven et al., 2011; 
www.intechopen.com
 New Advances in the Basic and Clinical Gastroenterology 
 
468 
Vinciguerra 2011). A recent systematic review evaluating retrospective and prospective 
studies on neo-adjuvant chemo-radiotherapy from 1966 to 2009 included a total of 111 
studies and 4,394 patients suggests that up to one third of patients with previously 
borderline resectable cancers are eligible for resection after neoadjuvant treatment (Gillen et 
al. 2010). More importantly, these patients were found to have comparable median survival 
as those who undergoing resection followed by adjuvant therapy (20.1 vs. 23.6 months, 
respectively). In contrast, neoadjuvant therapy did not seem to improve overall outcome for 
patients with resectable cancer at presentation (Gillen et al. 2010). 
In contrast to pancreatic cancer, cholangiocarcinoma has been shown to be resistant to 
common chemotherapy (Anderson and Kim, 2009). Numerous drugs have been tested 
alone and in combination, and thus far, the response rate has been unacceptably low. 
Although gemcitabine chemotherapy is often given to patients with unresectable 
cholangiocarcinoma, the survival benefit has not been proven in a randomised controlled 
trial (Gruenberger et al. 2010).  
5. Palliative endoscopic interventions 
Given that up to 80-85% of pancreato-biliary cancers are unresectable and the survival 
benefit of chemo-radiation therapy is very modest, palliative treatment plays a very 
important role in the care of these patients. Relief of symptoms secondary to gastro-
duodenal obstruction, jaundice and pain are essential to improve their quality of life and 
overall survival. In the past, surgical palliative approaches, such as gastric bypass and 
hepatico-enteric decompression, are more common used as the diagnosis of unresectable 
disease is frequently made in the operating room. With the recent improvement in pre-
operative staging, diagnostic laparotomy is rarely performed and biliary or gastro-duodenal 
obstruction is mostly managed by minimally invasive endoscopic interventions.  
5.1 Alleviation of biliary obstruction 
Currently, endoscopic biliary stenting is the treatment of choice for unresectable pancreato-
biliary cancers with obstructive jaundice (Figure 4). Endoscopic placement of plastic stent(s) 
was equally effective as surgical technique in palliating obstructive jaundice, but endoscopic 
stent was associated with fewer procedural complications and death (Taylor et al., 2000). 
More recently, the invention of larger diameter self-expandable metallic (SEM) biliary stents 
provides longer stent patency for drainage. Compared to plastic stents, SEM stents are 
significantly less likely to be occluded and thus, minimized the number of repeated ERCP. 
As with plastic stents, endoscopic placement of SEM stents has been shown to provide 
similar overall survival to surgical decompression but is more cost-effective and better 
quality of life (Knyrim et al., 1993; Prat et al., 1998). The concurrent use of chemotherapeutic 
agents in patients palliated with SEM stents does not increase the risk for ascending 
cholangitis (Nakai et al., 2005). 
Percutaneous trans-hepatic stenting (PTHS) is often reserved for patients in whom ERCP 
has failed due to a higher complication rate as well as poorer quality of life (Pinol et al., 
2002). More recently, the advent of EUS assisted ductal drainage and stenting has 
significantly improved the success rate of endoscopic approach and thus, reduced the need 
for PTHS. This approach involves puncturing a dilated intra-hepatic duct, under direct EUS  
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Fig. 4. Examples of biliary obstruction from pancreatic cancer requiring biliary drainage 
using plastic biliary stent (panel A) and SEM biliary stent (panel B). 
guidance, to pass a guide wire into the duodenum, which then allows successful canulation 
of the biliar tree via ERCP and stenting (Shami and Kahaleh, 2007). In cases of duodenal 
obstruction, direct biliary drainage from a dilated intrahepatic duct into the stomach or 
duodenum via a SEM is an effective alternative for palliation with reasonable safety profile 
(Iwamuro et al., 2010; Nguyen-Tang et al. 2010). Surgical biliary bypass is only considered 
for patients who have relatively preserved functional status with obstructive jaundice and 
have failed on endoscopic stent placement.  
5.2 Alleviation of gastro-duodenal obstruction 
Although gastric bypass is commonly performed for unresectable patients with gastro-
duodenal obstruction, the introduction of self-expanding metallic duodenal stents has 
changed the options for palliation (Figure 5). Current data suggest that placement of self-
expandable metallic duodenal stents for malignant gastric outlet obstruction is successful in 
98% of cases with a median duration of patency of 10 months (van Hooft et al., 2009). 
Serious complications from duodenal stenting, such as gastrointestinal bleeding or 
perforation, are rare with long-term stent dysfunction occurs in 14% of patients and 
migration in only 2% (van Hooft et al., 2009). Compared with palliative surgery, stent 
placement provides a shorter hospital stay, earlier resumption of oral intake, fewer 
complications and lower hospital costs (Maetani et al., 2004; Maetani et al., 2005). Currently, 
surgical palliation is often reserved for patients who are expected have a long life-
expectancy and need both biliary and gastric bypass. 
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Fig. 5. A case of duodenal obstruction caused by locally advanced pancreatic cancer (A) and 
was successfully treated with a SEM duodenal stent (B).This patient also had a SEM biliary 
stent inserted for biliary drainage prior to the duodenal stent placement (C). 
5.3 Alleviation of pain 
Approximately 70% of patients with unresectable pancreato-biliary cancer develop clinically 
important pain, which can significantly reduce the quality and quantity of life of these 
patients (Andren-Sandberg et al., 1999). Good pain relief is, therefore, an essential part of 
effective palliative care. Although opioid analgesics are most commonly used as the first line 
pain relieved medication, one third of patients experience inadequate control of pain with 
significant side effects such as constipation and drowsiness (Andren-Sandberg et al., 1999). 
In these patients, neurolytic celiac plexus block under radiological or surgical guidance with 
absolute alcohol can be performed with up to 90% success rate (Mercadante et al., 2003; 
Wong et al., 2004; Noble and Gress, 2006). Recent studies have shown that EUS-guided 
neurolysis is equally effective but has significantly fewer serious complications associated 
with surgical or percutaneous approaches (O'Toole and Schmulewitz, 2009; Puli et al., 2009)  
 
Fig. 6. Celiac ganglia can be visualized clearly on EUS imaging (panel A). Examples of EUS 
guided celiac ganglion blockage with alcohol injection (panel B). 
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(Figure 6). A recent double-blind randomized controlled study has also found that celiac 
plexus block is superior than systemic analgesic therapy in providing pain relief and 
improving quality of life (Wong et al., 2004). Thus, EUS-guided celiac neurolysis should be 
considered in all patients who have abdominal pain related to the pancreato-biliary cancer.  
6. Conclusions 
Despite the recent advances in diagnostic modalities, chemo-radiotherapy, surgical and 
post-operative care, the overall prognosis of pancreato-biliary malignancies has barely 
changed over the last few decades. The management of these patients is often complex and 
requires expertise in many fields. Thus, multidisciplinary teams are necessary to optimize 
the overall care. As the majority of these patients are diagnosed in advanced stages, good 
palliative care measures are essential to the management. Fortunately, a number of 
advances in endoscopic techniques have been made to improve the quality of life of these 
patients and avoid unnecessary surgery.  
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